Anti-KIR2DL2/KIR2DL3 Monoclonal Antibody for WB, IF/ICC, FC, ELISA - P43628

Core Product Specifications and Parameters

Biological Background: KIR2DL2/KIR2DL3 Function and Localization

• KIR2DL3 (Killer cell immunoglobulin-like receptor 2DL3, also known as CD158b, p58 NK receptor, NKAT2) is a type I transmembrane glycoprotein member of the KIR family. It functions as an inhibitory receptor on natural killer (NK) cells for specific HLA-C allotypes, including HLA-Cw1, Cw3, and Cw7.
• The receptor contains two extracellular immunoglobulin-like C2-type domains, a single transmembrane helix, and a cytoplasmic tail with immunoreceptor tyrosine-based inhibitory motifs (ITIMs) that recruit phosphatases to block activating signals.
• KIR2DL3 expression is largely restricted to NK cells, where it mediates self-tolerance and patrols for missing-self through monitoring MHC class I expression on target cells.
• Engagement of KIR2DL3 by its ligand suppresses NK cell-mediated cytotoxicity, preventing lysis of healthy cells while allowing killing of cells that have downregulated HLA-C.
• The extracellular domain undergoes N‑linked glycosylation and disulfide bond formation, contributing to the observed multiple molecular weight forms (~27 kDa non-glycosylated and ~37–38 kDa glycosylated).
• KIR2DL2, encoded by a distinct gene, shares approximately 96% amino acid identity with KIR2DL3 and exhibits similar HLA‑C specificity; the antibody’s immunogen (aa 22‑245 of KIR2DL3) spans a region conserved between both receptors, enabling cross‑detection.
• Alternative splicing of the KIR2DL3 transcript can produce variants with altered ligand binding or signaling properties, though the full‑length isoform is the predominant functional form.

Experimental Guidance and Technical Tips

• For Western blotting, expect bands around 27 kDa (non-glycosylated) and 37–38 kDa (glycosylated form). Use reducing conditions and load total lysates from KIR-positive NK cell lines (e.g., NK92, YTS) as positive controls. Consider deglycosylation with PNGase F to simplify band pattern.
• As the immunogen covers the extracellular domain, the antibody recognizes native surface receptor; for flow cytometry and immunofluorescence, no permeabilization is needed for surface staining. Titrate the antibody and include an isotype control to ensure specificity on human PBMCs or isolated NK cells.
• For ELISA applications, this monoclonal antibody can serve as capture or detection reagent; if building a sandwich immunoassay, pair with a binder to a separate epitope. Validate with recombinant KIR2DL3 protein or cell lysates.
• Confirm cross‑reactivity to KIR2DL2 by testing in cell lines expressing each receptor individually (e.g., 293T transfectants), given the high sequence homology.
• Due to KIR polymorphism, staining patterns may vary between donors; optimize antibody concentration for each application and cell type.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides diagnostic manufacturers, laboratories, and research institutes with one-stop access to IVD raw materials, technical services, and consulting. Our portfolio includes validated antibody pairs, optimized monoclonal and polyclonal antibodies, bulk ancillary reagents, and rare-target sourcing to support immuno-oncology and natural killer cell research. With this anti-KIR2DL2/KIR2DL3 monoclonal antibody, we enable precise receptor detection for functional assays and diagnostic development.